siRNAs
(小干扰RNA)
siRNAs（小干扰 RNA）是短片段的外源性双链 RNA（dsRNA）（20-25 个核苷酸），其能够触发RNA干扰（RNAi）途径。siRNA进入细胞后发生解链，正义链被降解的同时反义链与各种蛋白质成分形成RNA诱导沉默复合物（RISC）。RISC中保留的反义链与靶基因mRNA特异性互补。同时，RISC具有核酸酶活性，能够切割并降解靶基因mRNA，从而抑制靶基因的表达。而siRNA和靶基因序列的不完全互补会导致 mRNA 翻译抑制。
siRNA和套装定制服务
siRNAs (small interfering RNAs) are small exogenous double-stranded RNA (dsRNA) (20-25 nucleotides), which trigger the RNA interference (RNAi) pathway. The short dsRNA unwinds and the sense strand is degraded. Antisense strand forms RNA induced silencing complex (RISC) with various protein components. The antisense strand retained in RISC is specifically complementary to the target gene mRNA. Meanwhile, RISC has nuclease activity, which can cut and degrade the target gene mRNA, and inhibit the expression of target gene. Incomplete complementarity results in mRNA translation inhibition.
siRNA Synthesis Services
| Cat. No. |
Product Name |
CAS No. |
Purity |
Chemical Structure |
-
- HY-132591A
-
-
RNA, (Am-sp-(2'-deoxy-2'-fluoro)C-sp-Am-(2'-deoxy-2'-fluoro)A-(2'-deoxy-2'- fluoro)A-(2'-deoxy-2'-fluoro)A-Gm-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)AAm-(2'-deoxy-2'-fluoro)A-Cm-(2'-deoxy-2'-fluoro)A-Gm-(2'-deoxy-2'-fluoro)G-Um-(2'-deoxy-2'-fluoro)C-Um-Am-Gm-sp-Am-sp-Am), complex with RNA (Cm-sp-Umsp -Am-Gm-Am-Cm-(2'-deoxy-2'-fluoro)C-Um-(2'-deoxy-2'-fluoro)G-Um-dT-UmUm-Gm-Cm-Um-Um-Um-Um-Gm-Um) 3'-[[(2S,4R)-1-[29-[[2-(acetylamino)-2- deoxy-β-D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-βD-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]- 1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2- pyrrolidinyl]methyl hydrogen phosphate] (1:1), sodium salt
RNA, (Am-sp-(2'-deoxy-2'-fluoro)C-sp-Am-(2'-deoxy-2'-fluoro)A-(2'-deoxy-2'- fluoro)A-(2'-deoxy-2'-fluoro)A-Gm-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)AAm-(2'-deoxy-2'-fluoro)A-Cm-(2'-deoxy-2'-fluoro)A-Gm-(2'-deoxy-2'-fluoro)G-Um-(2'-deoxy-2'-fluoro)C-Um-Am-Gm-sp-Am-sp-Am), complex with RNA (Cm-sp-Umsp -Am-Gm-Am-Cm-(2'-deoxy-2'-fluoro)C-Um-(2'-deoxy-2'-fluoro)G-Um-dT-UmUm-Gm-Cm-Um-Um-Um-Um-Gm-Um) 3'-[[(2S,4R)-1-[29-[[2-(acetylamino)-2- deoxy-β-D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-βD-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]- 1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2- pyrrolidinyl]methyl hydrogen phosphate] (1:1), sodium salt
-
- HY-150150
-
|
SiRNA Negative Control
|
|
99.24% |
|
SiRNA Negative Control 是一个 21 个核苷酸的 siRNA，可用作阴性对照。SiRNA Negative Control 与大多数已知基因序列均无同源性。SiRNA Negative Control 可用于体外人、小鼠和大鼠细胞。SiRNA Negative Control 可作为实验对照基准，验证实验的可靠性并作为标准化参考。SiRNA Negative Control 是文献中普遍使用的一种阴性对照。
|
-
RNA, (UUCUCCGAACGUGUCACGUUU), complex with RNA, (ACGUGACACGUUCGGAGAAUU) (1:1)
RNA, (UUCUCCGAACGUGUCACGUUU), complex with RNA, (ACGUGACACGUUCGGAGAAUU) (1:1)
-
- HY-132609
-
|
Patisiran sodium
|
1386913-72-9 |
99.09% |
|
Patisiran sodium 是一种双链小干扰 RNA，靶向 Transthyretin (TTR) 信使 RNA 内的序列。Patisiran sodium 特异性抑制突变体和野生型 TTR 的肝脏合成。Patisiran sodium 可用于研究遗传性 TTR 淀粉样蛋白症的研究。
|
-
RNA, (A-U-G-G-A-A-Um-A-C-U-C-U-U-G-G-U-Um-A-C-dT-dT), complex with RNA (G-Um-A-ACm-Cm-A-A-G-A-G-Um-A-Um-Um-Cm-Cm-A-Um-dT-dT) (1:1) sodium salt
RNA, (A-U-G-G-A-A-Um-A-C-U-C-U-U-G-G-U-Um-A-C-dT-dT), complex with RNA (G-Um-A-ACm-Cm-A-A-G-A-G-Um-A-Um-Um-Cm-Cm-A-Um-dT-dT) (1:1) sodium salt
-
- HY-132610A
-
|
Givosiran sodium
|
1639325-44-2 |
98.71% |
|
Givosiran (ALN-AS1) sodium 是一种小干扰 RNA，靶向肝脏氨基纤维素合酶 1 (ALAS1) 信使 RNA。Givosiran sodium 下调 ALAS1 mRNA 并阻止神经毒性 δ-氨基纤维酸 (ALA) 和胆色素原 (PBG) 的积累。Givosiran sodium 在小鼠、大鼠和食蟹猴模型中均展现出强大的对 ALAS1 的抑制能力。Givosiran sodium 可用于急性肝性卟啉症 (AHP) 的研究。
|
-
RNA, (Cm-sp-Am-sp-Gm-Am-Am-Am-(2′-deoxy-2′-fluoro)G-Am-(2′-deoxy-2′-fluoro)G-Um-(2′-deoxy-2′-fluoro)G-Um-(2′-deoxy-2′-fluoro)C-Um-(2′-deoxy-2′-fluoro)C-Am-Um-Cm-Um-Um-Am), 3′-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate], complex with RNA (Um-sp-(2′-deoxy-2′-fluoro)A-sp-(2′-deoxy-2′-fluoro)A-(2′-deoxy-2′-fluoro)G-Am-(2′-deoxy-2′-fluoro)U-Gm-(2′-deoxy-2′-fluoro)A-Gm-(2′-deoxy-2′-fluoro)A-Cm-(2′-deoxy-2′-fluoro)A-Cm-(2′-deoxy-2′-fluoro)U-Cm-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)U-Cm-(2′-deoxy-2′-fluoro)U-Gm-sp-Gm-sp-Um), sodium salt (1:1:43)
RNA, (Cm-sp-Am-sp-Gm-Am-Am-Am-(2′-deoxy-2′-fluoro)G-Am-(2′-deoxy-2′-fluoro)G-Um-(2′-deoxy-2′-fluoro)G-Um-(2′-deoxy-2′-fluoro)C-Um-(2′-deoxy-2′-fluoro)C-Am-Um-Cm-Um-Um-Am), 3′-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate], complex with RNA (Um-sp-(2′-deoxy-2′-fluoro)A-sp-(2′-deoxy-2′-fluoro)A-(2′-deoxy-2′-fluoro)G-Am-(2′-deoxy-2′-fluoro)U-Gm-(2′-deoxy-2′-fluoro)A-Gm-(2′-deoxy-2′-fluoro)A-Cm-(2′-deoxy-2′-fluoro)A-Cm-(2′-deoxy-2′-fluoro)U-Cm-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)U-Cm-(2′-deoxy-2′-fluoro)U-Gm-sp-Gm-sp-Um), sodium salt (1:1:43)
-
- HY-132591
-
-
RNA, (Am-sp-(2'-deoxy-2'-fluoro)C-sp-Am-(2'-deoxy-2'-fluoro)A-(2'-deoxy-2'- fluoro)A-(2'-deoxy-2'-fluoro)A-Gm-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)AAm-(2'-deoxy-2'-fluoro)A-Cm-(2'-deoxy-2'-fluoro)A-Gm-(2'-deoxy-2'-fluoro)G-Um-(2'-deoxy-2'-fluoro)C-Um-Am-Gm-sp-Am-sp-Am), complex with RNA (Cm-sp-Umsp -Am-Gm-Am-Cm-(2'-deoxy-2'-fluoro)C-Um-(2'-deoxy-2'-fluoro)G-Um-dT-UmUm-Gm-Cm-Um-Um-Um-Um-Gm-Um) 3'-[[(2S,4R)-1-[29-[[2-(acetylamino)-2- deoxy-β-D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-βD-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]- 1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2- pyrrolidinyl]methyl hydrogen phosphate] (1:1)
RNA, (Am-sp-(2'-deoxy-2'-fluoro)C-sp-Am-(2'-deoxy-2'-fluoro)A-(2'-deoxy-2'- fluoro)A-(2'-deoxy-2'-fluoro)A-Gm-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)AAm-(2'-deoxy-2'-fluoro)A-Cm-(2'-deoxy-2'-fluoro)A-Gm-(2'-deoxy-2'-fluoro)G-Um-(2'-deoxy-2'-fluoro)C-Um-Am-Gm-sp-Am-sp-Am), complex with RNA (Cm-sp-Umsp -Am-Gm-Am-Cm-(2'-deoxy-2'-fluoro)C-Um-(2'-deoxy-2'-fluoro)G-Um-dT-UmUm-Gm-Cm-Um-Um-Um-Um-Gm-Um) 3'-[[(2S,4R)-1-[29-[[2-(acetylamino)-2- deoxy-β-D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-βD-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]- 1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2- pyrrolidinyl]methyl hydrogen phosphate] (1:1)
-
- HY-177640
-
|
Lepodisiran
|
2808361-18-2 |
|
|
Lepodisiran 是一种针对脂蛋白(a)的 siRNA。
|
-
RNA, ([4'-de(hydroxymethyl)-4'-[(hydroxymethoxyphosphinyl)methoxy]]Um-sp-(2'-deoxy-2'-fluoro)A-sp-(2'-deoxy-2'-fluoro)G-sp-(2'-deoxy-2'-fluoro)A-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)A-Cm-Cm-(2'-deoxy-2'-fluoro)A-Am-Gm-Cm-(2'-deoxy-2'-fluoro)U-Um-Gm-Gm-Cm-Am-Am-sp-Gm-sp-Gm), complex with RNA (Um-sp-Um-Gm-Cm-Cm-Am-Am-(2'-deoxy-2'-fluoro)G-(2'-deoxy2'-fluoro)C-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)U-Gm-Gm-Um-Cm-Am-Um-CmUm-Am-Gm-Cm-Am-Gm-Cm-Cm-Gm-[2'-O-[[2-[2-[[5-[[2-(acetylamino)-2-deoxy-β-Dgalactopyranosyl]oxy]-1-oxopentyl]amino]ethoxy]ethoxy]methyl]]A-[2'-O-[[2-[2-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]ethoxy]ethoxy]methyl]]A-[2'-O-[[2-[2-[[5-[[2-(acetylamino)-2-deoxy-βD-galactopyranosyl]oxy]-1-oxopentyl]amino]ethoxy]ethoxy]methyl]]A-Gm-Gm-CmUm-Gm-Cm) (1:1)
RNA, ([4'-de(hydroxymethyl)-4'-[(hydroxymethoxyphosphinyl)methoxy]]Um-sp-(2'-deoxy-2'-fluoro)A-sp-(2'-deoxy-2'-fluoro)G-sp-(2'-deoxy-2'-fluoro)A-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)A-Cm-Cm-(2'-deoxy-2'-fluoro)A-Am-Gm-Cm-(2'-deoxy-2'-fluoro)U-Um-Gm-Gm-Cm-Am-Am-sp-Gm-sp-Gm), complex with RNA (Um-sp-Um-Gm-Cm-Cm-Am-Am-(2'-deoxy-2'-fluoro)G-(2'-deoxy2'-fluoro)C-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)U-Gm-Gm-Um-Cm-Am-Um-CmUm-Am-Gm-Cm-Am-Gm-Cm-Cm-Gm-[2'-O-[[2-[2-[[5-[[2-(acetylamino)-2-deoxy-β-Dgalactopyranosyl]oxy]-1-oxopentyl]amino]ethoxy]ethoxy]methyl]]A-[2'-O-[[2-[2-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]ethoxy]ethoxy]methyl]]A-[2'-O-[[2-[2-[[5-[[2-(acetylamino)-2-deoxy-βD-galactopyranosyl]oxy]-1-oxopentyl]amino]ethoxy]ethoxy]methyl]]A-Gm-Gm-CmUm-Gm-Cm) (1:1)
-
- HY-147266C
-
-
Elebsiran scramble negative control
Elebsiran scramble negative control
-
- HY-177971
-
|
Braxlosiran
|
|
|
|
Braxlosiran 是一种靶向 DUX4 (双同源框蛋白) 的 siRNA，是 AOC 药物 Delpacibart braxlosiran (HY-177566) 的组成成分之一。DUX4 蛋白的异常表达会导致肌肉细胞中基因表达的变化，这种变化与面肩肱型肌营养不良症 (FSHD) 肌肉功能丧失有关。
|
-
RNA (Cm-sp-Gm-sp-Am-Cm-Gm-Gm-(2′-deoxy-2′-fluoro)A-(2′-deoxy-2′-fluoro)G-(2′-deoxy-2′-fluoro)A-Cm-Um-Cm-Gm-Um-Um-Um-Gm-sp-Gm-sp-Am), 5′-[6-[[[4-[(3-mercapto-2,5-dioxo-1-pyrrolidinyl)methyl]cyclohexyl]carbonyl]amino]hexyl hydrogen phosphate], complex with RNA (Um-sp-(2′-deoxy-2′-fluoro)C-sp-Cm-Am-Am-(2′-deoxy-2′-fluoro)A-Cm-Gm-Am-Gm-Um-Cm-Um-(2′-deoxy-2′-fluoro)C-Cm-(2′-deoxy-2′-fluoro)G-Um-Cm-Gm-sp-Um-sp-Um)
RNA (Cm-sp-Gm-sp-Am-Cm-Gm-Gm-(2′-deoxy-2′-fluoro)A-(2′-deoxy-2′-fluoro)G-(2′-deoxy-2′-fluoro)A-Cm-Um-Cm-Gm-Um-Um-Um-Gm-sp-Gm-sp-Am), 5′-[6-[[[4-[(3-mercapto-2,5-dioxo-1-pyrrolidinyl)methyl]cyclohexyl]carbonyl]amino]hexyl hydrogen phosphate], complex with RNA (Um-sp-(2′-deoxy-2′-fluoro)C-sp-Cm-Am-Am-(2′-deoxy-2′-fluoro)A-Cm-Gm-Am-Gm-Um-Cm-Um-(2′-deoxy-2′-fluoro)C-Cm-(2′-deoxy-2′-fluoro)G-Um-Cm-Gm-sp-Um-sp-Um)
-
- HY-143221
-
|
AS-Inclisiran sodium
|
|
|
|
AS-Inclisiran sodium 是 Inclisiran 的反义链。Inclisiran (ALN-PCSsc) 是一种双链小干扰 RNA (siRNA) 分子，可抑制 PCSK-9 的转录。Inclisiran 可用于高脂血症和心血管疾病 (CVD) 研究。
|
-
AS-Inclisiran (sodium)
AS-Inclisiran (sodium)
-
- HY-143219
-
-
SS-Inclisiran (sodium)
SS-Inclisiran (sodium)
-
- HY-132610
-
|
Givosiran
|
1639325-43-1 |
|
|
Givosiran (ALN-AS1) 是一种小干扰 RNA，靶向肝脏氨基纤维素合酶 1 (ALAS1) 信使 RNA。Givosiran 下调 ALAS1 mRNA 并阻止神经毒性 δ-氨基纤维酸 (ALA) 和胆色素原 (PBG) 的积累。Givosiran 在小鼠、大鼠和食蟹猴模型中均展现出强大的对 ALAS1 的抑制能力。Givosiran 可用于急性肝性卟啉症 (AHP) 的研究。
|
-
RNA, (Cm-sp-Am-sp-Gm-Am-Am-Am-(2'-deoxy-2'-fluoro)G-Am-(2'-deoxy-2'-fluoro)G-Um-(2'-deoxy-2'-fluoro)G-Um-(2'-deoxy-2'-fluoro)C-Um-(2'-deoxy-2'-fluoro)C-Am-Um-Cm-Um-Um-Am), 3'-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]- 14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate], complex with RNA (Um-sp-(2'-deoxy-2'-fluoro)A-sp-(2'-deoxy-2'-fluoro)A-(2'-deoxy-2'-fluoro)G-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)A-Gm-(2'-deoxy-2'-fluoro)A-Cm-(2'-deoxy-2'-fluoro)A-Cm-(2'-deoxy-2'-fluoro)U-Cm-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)U-Cm-(2'-deoxy-2'-fluoro)U-Gm-sp-Gm-sp-Um) (1:1)
RNA, (Cm-sp-Am-sp-Gm-Am-Am-Am-(2'-deoxy-2'-fluoro)G-Am-(2'-deoxy-2'-fluoro)G-Um-(2'-deoxy-2'-fluoro)G-Um-(2'-deoxy-2'-fluoro)C-Um-(2'-deoxy-2'-fluoro)C-Am-Um-Cm-Um-Um-Am), 3'-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]- 14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate], complex with RNA (Um-sp-(2'-deoxy-2'-fluoro)A-sp-(2'-deoxy-2'-fluoro)A-(2'-deoxy-2'-fluoro)G-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)A-Gm-(2'-deoxy-2'-fluoro)A-Cm-(2'-deoxy-2'-fluoro)A-Cm-(2'-deoxy-2'-fluoro)U-Cm-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)U-Cm-(2'-deoxy-2'-fluoro)U-Gm-sp-Gm-sp-Um) (1:1)
-
- HY-132588
-
|
Lumasiran
|
1834610-13-7 |
98.77% |
|
Lumasiran (ALN-G01) 是一种 siRNA 化合物，通过靶向乙醇酸氧化酶 (glycolate oxidase) 减少肝脏草酸的产生。Lumasiran 通过沉默编码乙醇酸氧化酶的基因，消耗乙醇酸氧化酶，从而抑制草酸的合成，草酸是一种与原发性高草酸尿1型 (PH1) 表现直接相关的有毒代谢物。
|
-
RNA, (Gm-sp-Am-sp-Cm-Um-Um-Um-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Um-Gm-Gm-Am-Am-Am-Um-Am-Um-Am),3'-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-Dgalactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-Dgalactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate], complex with RNA (Um-sp-(2'-deoxy2'-fluoro)A-sp-Um-Am-Um-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Am-Gm-Gm-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)A-Am-Am-Gm-Um-Cm-sp-Cm-sp-Am) (1:1)
RNA, (Gm-sp-Am-sp-Cm-Um-Um-Um-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Um-Gm-Gm-Am-Am-Am-Um-Am-Um-Am),3'-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-Dgalactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-Dgalactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate], complex with RNA (Um-sp-(2'-deoxy2'-fluoro)A-sp-Um-Am-Um-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Am-Gm-Gm-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)A-Am-Am-Gm-Um-Cm-sp-Cm-sp-Am) (1:1)
-
- HY-132613
-
|
Lumasiran sodium
|
1834612-06-4 |
99.21% |
|
Lumasiran sodium 是一种研究性 RNA 干扰 (RNAi) 剂，通过靶向乙醇酸氧化酶(glycolate oxidase) 减少肝脏草酸的产生。Lumasiran sodium 减少尿草酸排泄，这是原发性高草酸尿 1 型 (PH1) 进行性肾衰竭的原因。
|
-
RNA, (Gm-sp-Am-sp-Cm-Um-Um-Um-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'- fluoro)U-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Um-Gm-Gm-Am-Am-Am-Um-Am-Um-Am),3'-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-Dgalactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-Dgalactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate], complex with RNA (Um-sp-(2'-deoxy2'-fluoro)A-sp-Um-Am-Um-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Am-Gm-Gm-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'- fluoro)A-Am-Am-Gm-Um-Cm-sp-Cm-sp-Am) (1:1) sodium salt
RNA, (Gm-sp-Am-sp-Cm-Um-Um-Um-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'- fluoro)U-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Um-Gm-Gm-Am-Am-Am-Um-Am-Um-Am),3'-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-Dgalactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-Dgalactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate], complex with RNA (Um-sp-(2'-deoxy2'-fluoro)A-sp-Um-Am-Um-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Am-Gm-Gm-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'- fluoro)A-Am-Am-Gm-Um-Cm-sp-Cm-sp-Am) (1:1) sodium salt
-
- HY-147425A
-
-
RNA, (Am-sp-(2′-deoxy-2′-fluoro)U-sp-Am-(2′-deoxy-2′-fluoro)A-Cm-(2′-deoxy-2′-fluoro)U-Cm-(2′-deoxy-2′-fluoro)U-Gm-(2′-deoxy-2′-fluoro)U-Cm-(2′-deoxy-2′-fluoro)C-Am-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)A-Cm-sp-(2′-deoxy-2′-fluoro)C-sp-Gm), complex with RNA (Cm-Gm-Gm-Um-Am-Am-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)G-(2′-deoxy-2′-fluoro)G-Am-Cm-Am-Gm-Am-Gm-Um-Um-sp-Am-sp-Um) 5′-[O-[21-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-9,9-bis[12-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-7-mercapto-7-oxido-2,6,8-trioxa-7-phosphadodec-1-yl]-16-mercapto-16-oxido-7,11,15,17-tetraoxa-16-phosphaheneicos-1-yl] hydroxy phosphate] (1:1), sodium salt
RNA, (Am-sp-(2′-deoxy-2′-fluoro)U-sp-Am-(2′-deoxy-2′-fluoro)A-Cm-(2′-deoxy-2′-fluoro)U-Cm-(2′-deoxy-2′-fluoro)U-Gm-(2′-deoxy-2′-fluoro)U-Cm-(2′-deoxy-2′-fluoro)C-Am-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)A-Cm-sp-(2′-deoxy-2′-fluoro)C-sp-Gm), complex with RNA (Cm-Gm-Gm-Um-Am-Am-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)G-(2′-deoxy-2′-fluoro)G-Am-Cm-Am-Gm-Am-Gm-Um-Um-sp-Am-sp-Um) 5′-[O-[21-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-9,9-bis[12-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-7-mercapto-7-oxido-2,6,8-trioxa-7-phosphadodec-1-yl]-16-mercapto-16-oxido-7,11,15,17-tetraoxa-16-phosphaheneicos-1-yl] hydroxy phosphate] (1:1), sodium salt
-
- HY-132606A
-
|
Nedosiran sodium
奈多西兰钠盐
|
2247026-22-6 |
|
|
Nedosiran sodium 是一种靶向乳酸脱氢酶 (LDH) 的 RNA 干扰剂 (RNAi)。Nedosiran sodium 可用于研究并发终末期肾病 (ESRD) 的原发性高草酸尿症 (PH)。Nedosiran sodium 是一种 GalNAc-dsRNA 偶联物。
|
-
RNA, (Am-sp-Um-(2′-deoxy-2′-fluoro)G-Um-(2′-deoxy-2′-fluoro)U-Gm-Um-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)A-Um-(2′-deoxy-2′-fluoro)C-Um-Gm-Am-Gm-Cm-Am-Gm-Cm-Cm-[2′-O-[[2-[2-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]ethoxy]ethoxy]methyl]]G-[2′-O-[[2-[2-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]ethoxy]ethoxy]methyl]]A-[2′-O-[[2-[2-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]ethoxy]ethoxy]methyl]]A-[2′-O-[[2-[2-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]ethoxy]ethoxy]methyl]]A-Gm-Gm-Cm-Um-Gm-Cm), sodium salt, complex with RNA ([1-de-β-D-ribofuranosyl-1-[(2R,3R,4S,5R)-tetrahydro-4-hydroxy-5-[(hydroxymethoxyphosphinyl)methoxy]-3-methoxy-2-furanyl]]U-(4′→5′)-sp-(2′-deoxy-2′-fluoro)C-sp-(2′-deoxy-2′-fluoro)A-sp-(2′-deoxy-2′-fluoro)G-(2′-deoxy-2′-fluoro)A-Um-(2′-deoxy-2′-flu
RNA, (Am-sp-Um-(2′-deoxy-2′-fluoro)G-Um-(2′-deoxy-2′-fluoro)U-Gm-Um-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)A-Um-(2′-deoxy-2′-fluoro)C-Um-Gm-Am-Gm-Cm-Am-Gm-Cm-Cm-[2′-O-[[2-[2-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]ethoxy]ethoxy]methyl]]G-[2′-O-[[2-[2-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]ethoxy]ethoxy]methyl]]A-[2′-O-[[2-[2-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]ethoxy]ethoxy]methyl]]A-[2′-O-[[2-[2-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]ethoxy]ethoxy]methyl]]A-Gm-Gm-Cm-Um-Gm-Cm), sodium salt, complex with RNA ([1-de-β-D-ribofuranosyl-1-[(2R,3R,4S,5R)-tetrahydro-4-hydroxy-5-[(hydroxymethoxyphosphinyl)methoxy]-3-methoxy-2-furanyl]]U-(4′→5′)-sp-(2′-deoxy-2′-fluoro)C-sp-(2′-deoxy-2′-fluoro)A-sp-(2′-deoxy-2′-fluoro)G-(2′-deoxy-2′-fluoro)A-Um-(2′-deoxy-2′-flu
-
- HY-132587
-
|
Fitusiran
|
1499251-18-1 |
|
|
Fitusiran (ALN-AT3SC) 是一种小干扰 RNA，专门针对抗凝血酶 (AT) 信使 RNA，以降低肝脏中 AT 的产生。Fitusiran 增加凝血酶的生成，并可用于血友病的研究。
|
-
RNA, ((2'-deoxy-2'-fluoro)G-sp-Gm-sp-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)A-Am- (2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)A-Um-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)A-Cm-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)A),3'-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-Dgalactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate], complex with RNA (Um-sp-(2'-deoxy-2'-fluoro)U-sp-Gm-(2'-deoxy2'-fluoro)A-Am-(2'-deoxy-2'-fluoro)G-Um-(2'-deoxy-2'-fluoro)A-Am-(2'-deoxy-2'-fluoro)A-Um-Gm-Gm-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)A-Am-(2'-deoxy-2'-fluoro)C-Cm-sp-Am-sp-Gm)
RNA, ((2'-deoxy-2'-fluoro)G-sp-Gm-sp-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)A-Am- (2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)A-Um-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)A-Cm-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)A),3'-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-Dgalactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate], complex with RNA (Um-sp-(2'-deoxy-2'-fluoro)U-sp-Gm-(2'-deoxy2'-fluoro)A-Am-(2'-deoxy-2'-fluoro)G-Um-(2'-deoxy-2'-fluoro)A-Am-(2'-deoxy-2'-fluoro)A-Um-Gm-Gm-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)A-Am-(2'-deoxy-2'-fluoro)C-Cm-sp-Am-sp-Gm)
-
- HY-132589A
-
|
Vutrisiran sodium
|
|
|
|
Vutrisiran sodium 是一种肝脏导向的、小干扰RNA (siRNA) 。 Vutrisiran sodium 靶向转甲状腺素蛋白 (TTR) 的mRNA，可用于转甲状腺素蛋白 (TTR) 介导的淀粉样变性研究。
|
-
RNA, (Um-sp-(2'-deoxy-2'-fluoro)C-sp-Um-Um-Gm-(2'-deoxy-2'-fluoro)G-UmUm-(2'-deoxy-2'-fluoro)A-Cm-Am-Um-Gm-(2'-deoxy-2'-fluoro)A-Am-(2'-deoxy2'-fluoro)A-Um-Cm-Cm-Cm-Am-sp-Um-sp-Cm), complex with RNA (Um-sp-Gm-sp-Gm-Gm-Am-Um-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)A-(2'-deoxy-2'-fluoro)U-Gm-Um-Am-Am-Cm-Cm-Am-Am-GmAm) 3'-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate] (1:1), sodium salt
RNA, (Um-sp-(2'-deoxy-2'-fluoro)C-sp-Um-Um-Gm-(2'-deoxy-2'-fluoro)G-UmUm-(2'-deoxy-2'-fluoro)A-Cm-Am-Um-Gm-(2'-deoxy-2'-fluoro)A-Am-(2'-deoxy2'-fluoro)A-Um-Cm-Cm-Cm-Am-sp-Um-sp-Cm), complex with RNA (Um-sp-Gm-sp-Gm-Gm-Am-Um-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)A-(2'-deoxy-2'-fluoro)U-Gm-Um-Am-Am-Cm-Cm-Am-Am-GmAm) 3'-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate] (1:1), sodium salt
-
- HY-150223
-
|
GalNAc unconjugated/naked Inclisiran
|
|
|
|
GalNAc unconjugated/naked Inclisiran 是一种没有偶联 GalNAc 的双链小干扰 RNA (siRNA) 分子，可抑制 PCSK-9 的转录。GalNAc unconjugated/naked Inclisiran 可用于高脂血症和心血管疾病 (CVD) 研究。
|
-
GalNAc unconjugated/naked Inclisiran
GalNAc unconjugated/naked Inclisiran
-
- HY-143220
-
-
SS(no Galnac)-Inclisiran (sodium)
SS(no Galnac)-Inclisiran (sodium)
-
- HY-132596A
-
-
RNA, (A-A-G-C-G-C-A-U-C-U-U-C-U-A-C-U-U-C-A), complex with RNA (U-G-A-A-G-U-A-G-A-A-G-A-U-G-C-G-C-U-U) (1:1), sodium salt
RNA, (A-A-G-C-G-C-A-U-C-U-U-C-U-A-C-U-U-C-A), complex with RNA (U-G-A-A-G-U-A-G-A-A-G-A-U-G-C-G-C-U-U) (1:1), sodium salt
